Petros Pharmaceuticals, Inc. announced a new partnership with a leading, multi-billion-dollar AI software provider to adapt its technology for self-screening and other benefits as part of the Company's ongoing efforts to bring STENDRA over the counter. The technology will be integrated into the core tool the Company has already developed as part of its Self-Selection Study, which is currently underway.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.415 USD | -2.15% | -9.29% | -70.57% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-70.57% | 2.91M | |
+18.97% | 45.34B | |
+41.98% | 40.42B | |
-10.06% | 37.92B | |
+31.15% | 31.75B | |
-7.79% | 27.71B | |
+13.32% | 26.52B | |
+43.05% | 13.96B | |
+31.28% | 12.44B | |
-7.41% | 11.26B |
- Stock Market
- Equities
- PTPI Stock
- News Petros Pharmaceuticals, Inc.
- Petros Pharmaceuticals Enters into Ai Licensing Agreement with Leading Multi-Billion-Dollar Software Provider